Key points are not available for this paper at this time.
Aims This randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of ezetimibe 10mg/day in patients with primary hypercholesterolemia.
Robert H. Knopp (Tue,) studied this question.